TARS Q3 2024 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+2471.8% YoY

Gross Profit

$45M93.3% margin

Operating Income

-$25M-52.3% margin

Net Income

-$23M-48.7% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+17.9%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$376M

Total Liabilities

$139M

Stockholders' Equity

$237M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$2M	+2471.8%
Gross Profit	$45M	$1M	+2903.7%
Operating Income	-$25M	-$41M	+38.5%
Net Income	-$23M	-$39M	+40.2%

Revenue Segments

Product

$48M100%